• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疫情期间的药学领导力:在不确定时期维护患者安全

Pharmacy Leadership Amid the Pandemic: Maintaining Patient Safety During Uncertain Times.

作者信息

Derrong Lin Irene, Hertig John B

机构信息

Purdue University, West Lafayette, IN, USA.

Butler University, Indianapolis, IN, USA.

出版信息

Hosp Pharm. 2022 Jun;57(3):323-328. doi: 10.1177/00185787211037545. Epub 2021 Aug 5.

DOI:10.1177/00185787211037545
PMID:35615490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9125128/
Abstract

The relentless surges of global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections that caused the Covid-19 disease had pressured researchers and regulators to develop effective treatments quickly. While studying these therapies amid the pandemic, threats to patient care were reported, including (1) maintaining adequate safeguards as clinical effectiveness and safety data evolves, (2) risks from online counterfeit medications, and (3) disruption of the global pharmaceutical supply chain. This article discusses these patient safety threats and suggests strategies that promote patient safety, foster medication intelligence, and mitigate drug shortages. As the world continues to develop safe and effective treatments for Covid-19, patient safety is paramount. In response to the World Health Organization (WHO) Global Safety Challenge: Medication Without Harm, leaders must establish effective approaches to improve medication safety during the pandemic. Successfully integrating these leadership strategies with current practices allows pharmacy leaders to implement robust systems to reduce errors, prevent harm, and advocate for patient safety.

摘要

导致新冠肺炎疫情的全球严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染持续激增,给研究人员和监管机构带来了迅速开发有效治疗方法的压力。在疫情期间研究这些疗法时,报告了对患者护理的威胁,包括(1)随着临床有效性和安全性数据的演变维持适当的保障措施,(2)在线假药带来的风险,以及(3)全球药品供应链的中断。本文讨论了这些患者安全威胁,并提出了促进患者安全、培养用药知识和缓解药品短缺的策略。随着世界继续为新冠肺炎开发安全有效的治疗方法,患者安全至关重要。为应对世界卫生组织(WHO)的全球安全挑战:无害用药,领导者必须建立有效的方法,以在疫情期间提高用药安全性。成功地将这些领导策略与当前实践相结合,使药房领导者能够实施强大的系统,以减少错误、预防伤害并倡导患者安全。

相似文献

1
Pharmacy Leadership Amid the Pandemic: Maintaining Patient Safety During Uncertain Times.疫情期间的药学领导力:在不确定时期维护患者安全
Hosp Pharm. 2022 Jun;57(3):323-328. doi: 10.1177/00185787211037545. Epub 2021 Aug 5.
2
Dynamic pharmacy leadership during the COVID-19 crisis: Optimizing patient care through formulary and drug shortage management.在 COVID-19 危机期间的动态药学领导力:通过处方集和药品短缺管理优化患者护理。
Am J Health Syst Pharm. 2020 Oct 30;77(22):1874-1884. doi: 10.1093/ajhp/zxaa219.
3
A new leadership role for pharmacists: a prescription for change.药剂师的新领导角色:变革的处方。
J Patient Saf. 2010 Mar;6(1):31-7. doi: 10.1097/PTS.0b013e3181d108cb.
4
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)针对轻度至中度症状的高危冠状病毒(COVID-19)患者的单克隆抗体疗法(存档)
5
Current Threats to Maintaining a Secure Pharmaceutical Supply Chain in an Online World.在网络世界中维持安全药品供应链面临的当前威胁。
Hosp Pharm. 2020 Apr;55(2):85-89. doi: 10.1177/0018578719868406. Epub 2019 Aug 16.
6
Managing the risk of shortages and medication errors with curares during the COVID-19 pandemic: a hospital pharmacy experience.在 COVID-19 大流行期间管理肌松药短缺和用药错误的风险:医院药学的经验。
Eur J Hosp Pharm. 2023 Dec 27;31(1):79-81. doi: 10.1136/ejhpharm-2020-002605.
7
Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective.在 COVID-19 大流行期间提供药学服务的建议和指导:中国视角。
Res Social Adm Pharm. 2021 Jan;17(1):1819-1824. doi: 10.1016/j.sapharm.2020.03.012. Epub 2020 Mar 26.
8
Guidelines for Leading a Safe Medication Error Reporting Culture.建立安全用药错误报告文化的指南。
Hosp Pharm. 2021 Oct;56(5):604-609. doi: 10.1177/0018578720931752. Epub 2020 Jun 8.
9
Visitor Restrictions During the COVID-19 Pandemic and Increased Falls With Harm at a Canadian Hospital: An Exploratory Study.COVID-19 大流行期间的访客限制与加拿大一家医院伤害性跌倒增加:一项探索性研究。
J Patient Saf. 2024 Sep 1;20(6):434-439. doi: 10.1097/PTS.0000000000001237. Epub 2024 Jun 26.
10
Addressing the Challenge of COVID-19: One Health Care Site's Leadership Response to the Pandemic.应对新冠疫情的挑战:一个医疗保健场所的领导层对大流行的应对措施。
Mayo Clin Proc Innov Qual Outcomes. 2021 Feb;5(1):151-160. doi: 10.1016/j.mayocpiqo.2020.11.001. Epub 2020 Dec 14.

本文引用的文献

1
Guidelines for Leading a Safe Medication Error Reporting Culture.建立安全用药错误报告文化的指南。
Hosp Pharm. 2021 Oct;56(5):604-609. doi: 10.1177/0018578720931752. Epub 2020 Jun 8.
2
The pharmacist's active role in combating COVID-19 medication misinformation.药剂师在抗击 COVID-19 用药错误信息方面的积极作用。
J Am Pharm Assoc (2003). 2021 Mar-Apr;61(2):e71-e74. doi: 10.1016/j.japh.2020.10.022. Epub 2020 Nov 4.
3
How Do We Combat Bogus Medicines in the Age of the COVID-19 Pandemic?在新冠疫情时代,我们如何打击假冒药品?
Am J Trop Med Hyg. 2020 Oct;103(4):1360-1363. doi: 10.4269/ajtmh.20-0903.
4
Big Data, Natural Language Processing, and Deep Learning to Detect and Characterize Illicit COVID-19 Product Sales: Infoveillance Study on Twitter and Instagram.大数据、自然语言处理和深度学习技术在检测和识别非法销售 COVID-19 产品中的应用:对 Twitter 和 Instagram 的 Infoveillance 研究。
JMIR Public Health Surveill. 2020 Aug 25;6(3):e20794. doi: 10.2196/20794.
5
The COVID-19 infodemic.新冠疫情信息疫情
Lancet Infect Dis. 2020 Aug;20(8):875. doi: 10.1016/S1473-3099(20)30565-X. Epub 2020 Jul 17.
6
COVID-19 Supply Chain Considerations for Prescription Drugs in Dermatology.
J Drugs Dermatol. 2020 Jun 1;19(6):666-667.
7
The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?新冠疫情对全球医疗产品供应的影响:为何印度仿制药对世界至关重要?
F1000Res. 2020 Apr 1;9:225. doi: 10.12688/f1000research.23057.1. eCollection 2020.
8
A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation.羟氯喹啉心脏安全性概况的药物警戒研究:对缓解 COVID-19 的潜在影响
J Clin Med. 2020 Jun 15;9(6):1867. doi: 10.3390/jcm9061867.
9
Correction to: Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.更正:在新冠疫情期间:为全球健康和公共安全建立积极的药品不良反应(ADR)和医疗器械事件(MDI)报告文化的重要性。
J Pharm Policy Pract. 2020 Jun 11;13:30. doi: 10.1186/s40545-020-00231-5. eCollection 2020.
10
India expands use of controversial drug for coronavirus despite safety concerns.
Nature. 2020 Jun 3. doi: 10.1038/d41586-020-01619-8.